Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences announced the enrollment of the first patient in Part 3, the final stage of the PF614-MPAR-102 clinical study evaluating its novel MPAR overdose-protection technology. The MPAR technology is engineered to provide active protection against oral overdose by restricting release when excessive doses are taken, addressing a key risk in opioid therapy.
Key figures
- Drug Name
- PF614-MPAR
- Phase Of Trial
- Final stage (Part 3 of PF614-MPAR-102)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.